Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update • Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 • Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab, our PD-1 agonist; reiterating top-line data anticipated by mid 2025 and H1 2026, respectively • IND submis ...

Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab, our PD-1 agonist; reiterating top-line data anticipated by mid 2025 and H1 2026, respectivelyIND submissions for ANB033 (anti-CD122 antagonist) and ANB101 (BDCA2 modulator) anticipated Q2 2024 an ...

All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous (SC) maintenance dosing of imsidolimab in GEMINI-2 through at least 24 weeks maintained clear to almost clear skin and none experienced a flareOf the remaining eight responding patients from GEMINI-1 re-randomized to placebo in GEMINI-2, 25% maintained clear to almost clear skin and 63% of these patients experienced a flareSafety and tolerability in GEMINI- ...

AnaptysBio, Inc. (ANAB) shares soared 14.3% in the last trading session to close at $24.34. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.1% loss over the past four weeks.The company is currently developing a robust portfolio of immune cell modulators, including two checkpoint agonists and a BTLA agonist, which are currently being evaluated in various mid-stage studies for the treatment of several autoimmune and inflammatory ...

Core Insights - Actym Therapeutics has appointed Thomas Smart as the new CEO, bringing 25 years of experience in the biopharmaceutical industry to lead the company through its next growth phase as it prepares for clinical evaluation of its lead candidate, ACTM-838 [1][3] Company Overview - Actym Therapeutics has developed a proprietary platform called S. Typhimurium-Attenuated Cancer Therapy (STACT), which aims to achieve comprehensive immunological reprogramming of the tumor microenvironment [2] - The lead candidate, ACTM-838, is designed to selectively accumulate in the tumor microenvironment and deliver two engineered payloads: IL-15 and STING [2][4] - The company’s approach utilizes a genetically modified bacterial vehicle for targeted anti-tumor effects, aiming to activate both innate and adaptive immune responses against tumors [4] Leadership and Strategy - Thomas Smart's extensive background includes leadership roles in various biotech companies, with a focus on translating innovative research into therapeutics [3] - Under Smart's leadership, Actym aims to move ACTM-838 into clinical trials in the second quarter of 2024 and expand its pipeline with additional candidates from the STACT platform [3] - The STACT approach is noted for its efficacy and safety advantages, leveraging a systemically administered bacterial vehicle for tissue-specific delivery of large nucleic acid payloads [3]

The stock market may have pulled back a bit from the all-time high reached late last month but the S&P 500 remains 7.4% higher in 2024. Technology stocks continue to be top performers with Super Micro Computer (NASDAQ:SMCI) leading the way with a 216% gain so far.However, analysts at the wealth management arm of Goldman Sachs think the tech sector may have run its course. They say it is time to start looking elsewhere. Investors would be better off taking the profits they’ve made in tech and deploying them ...

A powerfully bullish new analyst take on the company helped it rally on the market.Many stocks were wobbly over the past few trading days, but we can't say that about biotech AnaptysBio (ANAB -8.17%). The company's shares closed the week almost 8% higher in price, according to data compiled by S&P Global Market Intelligence, largely on the strength of a research note published by a high-profile and influential bank.Doing well by Wells FargoThat occurred on Thursday before market open, when Wells Fargo initi ...

Industry Overview - The Medical-Biomedical and Genetics industry is currently ranked 73 out of more than 250 industries according to Zacks Industry Rank, indicating a strong position relative to other segments [1][2] Company Performance - AnaptysBio has experienced positive earnings estimate revisions, with current quarter estimates improving from a loss of $1.57 per share to a loss of $1.56 per share, and current year estimates narrowing from a loss of $6.46 per share to a loss of $6.25 per share [2] - The company holds a Zacks Rank of 3 (Hold), which is considered a favorable signal for investors [2]

Core Viewpoint - AnaptysBio, Inc. has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which is expected to lead to increased buying pressure and a rise in stock price [1][2]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for AnaptysBio for the fiscal year ending December 2024 is projected at -$6.20 per share, reflecting a 2% decrease from the previous year's reported figure [5]. - Over the past three months, analysts have raised their earnings estimates for AnaptysBio by 2.9%, indicating a positive trend in earnings outlook [5]. Impact of Earnings Estimates on Stock Prices - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [3]. - Institutional investors utilize earnings estimates to determine the fair value of a company's shares, which influences their buying or selling actions, subsequently affecting stock prices [3]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [4]. - AnaptysBio's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [6][7].

AnaptysBio, Inc. (ANAB) closed the last trading session at $24.69, gaining 10.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $41.88 indicates a 69.6% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $20.07. While the lowest estimate of $20 indicates a 19% decline from the current price level, the most optimistic analyst ex ...